Drug-resistant bacteria, or superbugs, pose a serious threat to human health. Developing new antibacterial drugs requires a great deal of time, effort, expenditure, and scientific research, making it a less-attractive segment for investment by pharmaceutical companies. This research service focuses on the global antibacterial drugs (antibiotics) market, with particular focus on the antibiotics currently under development. A list of currently available and marketed antibacterial drugs under the approved antibacterial drug classes has been provided. Product and pipeline assessment for recently approved antibacterial drugs, antibacterials under FDA review, as well as phase 3 antibacterial drug candidates have been provided. A detailed overview of the various regulatory approaches to foster innovation in the development of new antibiotics has been provided as well.
Executive Summary—Key Findings
Executive Summary—Key Findings (continued)
Executive Summary—Key Findings (continued)
Antibacterial Drugs Market—Game-changing Strategies
Key Merger, Acquisition, and Partnership Assessment
Key Merger, Acquisition, and Partnership Assessment (continued)
Key Merger, Acquisition, and Partnership Assessment (continued)
Key Merger, Acquisition, and Partnership Assessment (continued)
Key Merger, Acquisition, and Partnership Assessment (continued)
Methodology and Scope
Introduction
Introduction (continued)
Market Overview—Segmentation
Antibacterial Drugs—Approved and Novel Product Classes Synopsis
Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)
Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)
Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)
Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)
Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)
Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)
Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)
Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)
Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)
Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)
Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)
Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)
Antibacterial Drugs—Approved and Novel Product Classes Synopsis (continued)
Dosing Regimen of Commonly Prescribed Antigens
Dosing Regimen of Commonly Prescribed Antigens (continued)
Dosing Regimen of Commonly Prescribed Antigens (continued)
Dosing Regimen of Commonly Prescribed Antigens (continued)
Dosing Regimen of Commonly Prescribed Antigens (continued)
Dosing Regimen of Commonly Prescribed Antigens (continued)
Dosing Regimen of Commonly Prescribed Antigens (continued)
Dosing Regimen of Commonly Prescribed Antigens (continued)
Dosing Regimen of Commonly Prescribed Antigens (continued)
Dosing Regimen of Commonly Prescribed Antigens (continued)
Dosing Regimen of Commonly Prescribed Antigens (continued)
Dosing Regimen of Commonly Prescribed Antigens (continued)
Dosing Regimen of Commonly Prescribed Antigens (continued)
Dosing Regimen of Commonly Prescribed Antigens (continued)
Antibacterial Drugs—Competitive Landscape of Products in Development
Antibacterial Drugs—Pipeline Analysis
Antibacterial Drugs—Pipeline Synopsis
Antibacterial Drugs—Pipeline Synopsis (continued)
Antibacterial Drugs—Pipeline Synopsis (continued)
Antibacterial Drugs—Pipeline Synopsis (continued)
Antibacterial Drugs—Pipeline Synopsis (continued)
Antibacterial Drugs—Pipeline Synopsis (continued)
Antibacterial Drugs—Pipeline Synopsis (continued)
Antibacterial Drugs—Pipeline Synopsis (continued)
Antibacterial Drugs—Pipeline Synopsis (continued)
Antibacterial Drugs—Pipeline Synopsis (continued)
Antibacterial Drugs—Pipeline Synopsis (continued)
Antibacterial Drugs Market—Major Ongoing/Recently Completed Clinical Trials
Antibacterial Drugs Market—Major Ongoing/Recently Completed Clinical Trials (continued)
Antibacterial Drugs Market—Major Ongoing/Recently Completed Clinical Trials (continued)
Tedizolid Phosphate—Cubist Pharmaceuticals
Dalbavancin (Dalvance™)—Durata Therapeutics
Ceftolozane + Tazobactam—Cubist Pharmaceuticals
Oritavancin (Orbactiv™)—The Medicines Company
Ceftazidime + Avibactam (CAZ-AVI)—AstraZeneca
Cadazolid—Actelion Pharmaceuticals
Carbavance—Rempex Pharmaceuticals (The Medicines Company)
Delafloxacin—Melinta Therapeutics
Eravacycline—Tetraphase Pharmaceuticals
Plazomicin—Achaogen
Solithromycin—Cempra Pharmaceuticals
Surotomycin—Cubist Pharmaceuticals
Common Mechanisms of Antibiotic Resistance
Key Challenges to Antibiotic Research & Development
Hard-to-treat Pathogens/Superbugs That Pose a Serious Threat to Drug Makers
New Antibiotics in the Pipeline That Help Overcome Drug Resistance
New Antibiotics in the Pipeline That Help Overcome Drug Resistance (continued)
New Antibiotics in the Pipeline That Help Overcome Drug Resistance (continued)
New Antibiotics in the Pipeline That Help Overcome Drug Resistance (continued)
New Antibiotics in the Pipeline That Help Overcome Drug Resistance (continued)
Antibacterial Drug Classes—FDA Approval Timeline
Antibacterial Drug Classes—FDA Approval Timeline (continued)
Antibacterial Drugs—FDA Approval Timeline
Antibacterial Drugs Market—Timeline of Key Events
Antibacterial Drugs Market—Timeline of Key Events (continued)
Regulatory Policies to Stimulate Antibiotics R&D
Generating Antibiotics Incentives Now (GAIN) Act
Implementation of the (GAIN) Act
Antibiotic Development to Advance Patient Treatment Act (ADAPT): H.R. 3742
IDSA’s 10 x ‘20 Initiative
Additional Economic Incentives—Tax Credits
Additional Economic Incentives—Federal Research Funding
Additional Economic Incentives—Federal Research Funding (continued)
Additional Economic Incentives—Federal Research Funding (continued)
PPPs—The European Effort
PPPs—The European Effort (continued)
PPPs—BARDA
PPPs—BARDA (continued)
Key Companies to Watch
Key Companies to Watch (continued)
Conclusions and Recommendations
Legal Disclaimer
List of Abbreviations
The Frost & Sullivan Story
Value Proposition
Global Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Our Blue Ocean Strategy
Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.
Speak directly with our analytics experts for tailored recommendations.
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
Drug-resistant bacteria, or superbugs, pose a serious threat to human health. Developing new antibacterial drugs requires a great deal of time, effort, expenditure, and scientific research, making it a less-attractive segment for investment by pharmaceutical companies. This research service focuses on the global antibacterial drugs (antibiotics) market, with particular focus on the antibiotics currently under development. A list of currently available and marketed antibacterial drugs under the approved antibacterial drug classes has been provided. Product and pipeline assessment for recently approved antibacterial drugs, antibacterials under FDA review, as well as phase 3 antibacterial drug candidates have been provided. A detailed overview of the various regulatory approaches to foster innovation in the development of new antibiotics has been provided as well.
| Deliverable Type | Market Research |
|---|---|
| No Index | No |
| Podcast | No |
| Author | Aiswariya Chidambaram |
| WIP Number | MABA-01-00-00-00 |
| Keyword 1 | Antibacterial Drugs |
| Keyword 2 | Pipeline Analysis of Antibacterial Drugs |
| Keyword 3 | Antibacterial Drugs Product Analysis |
| Is Prebook | No |
A Product and Pipeline Analysis of the Antibacterial Drugs Market
A Product and Pipeline Analysis of the Antibacterial Drugs Market
Regulatory Approaches to Combat Microbial Resistance and Stimulate Antibiotics R&D
RELEASE DATE
22-Jan-2015
22-Jan-2015
REGION
North America
North America
Deliverable Type
Market Research
Market Research
Research Code: MABA-01-00-00-00
SKU: LS00179-NA-MR_17309
$3,950.00
In stock
SKU
LS00179-NA-MR_17309